A. Kundzer
11 Papers
24 Citations
A. Kundzer is an academic researcher. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 3, co-authored 8 publications.
Chat about Author
Papers
Ab0540 comparison of eq-5d health status in psoriatic arthritis patients with or without axial disease: results of subanalysis of the patera study
Inna Gaydukova,T. Korotaeva,V. Mazurov,A. V. Samtsov,V. Khayrutdinov,A. Bakulev,A. Kundzer,N. Soroka,A. Eremeeva +8 more
TL;DR: NTK resulted in the growing improvement of each EQ-5D-5L domain through 24 weeks irrespectively of the presence of IBP, andIBP(-) subjects showed trend to greater benefit compared to IBP(+).
Op0232 netakimab reduces the disease activity of radiographic axial spondyloarthritis. results of astera study
Inna Gaydukova,V. Mazurov,Shandor Erdes,Tatiana Dubinina,O. Nesmeyanova,Elena Ilivanova,A. Kundzer,N. Soroka,Aleksander Kastanayan,Tatyana Povarova,Elena Zhugrova,T. Plaksina,Pavel Shesternya,T. Kropotina,Olga Antipova,Elena A Smolyarchuk,Oksana Tciupa,Diana Abdulganieva,Diana Kretchikova,Ivan G. Gordeev,Tyrenko Vv,Aleksandra Strelkova,A. Eremeeva,E. Chernyaeva,Roman Ivanov +24 more
TL;DR: NTK at a dose 120 mg is well-tolerated drug with favorable safety profile that leads to decline in r-axSpA activity, function improvement and axial mobility in 16 Wks.
4
Fri0391 netakimab improves patient-related outcomes in patients with radiological axial spondyloarthritis: results from randomised phase 3 trial (astera)
Inna Gaydukova,Vadim I. Mazurov,Shandor Erdes,Tatiana Dubinina,O. Nesmeyanova,Elena Ilivanova,A. Kundzer,N. Soroka,E. Dokukina,A. Eremeeva,E. Chernyaeva,Roman Ivanov +11 more
TL;DR: NTK in treatment of patients with r-axSpA showed rapid improvement in PRO, WP and QoL and was accompanied with improvement in physical function and disease activity.
3
Pos0624 efficacy and safety of levilimab in combination with methotrexate in subjects with active rheumatoid arthritis: phase iii, double-blind, placebo-controlled, randomized trial
V. Mazurov,Maxim Aleksandrovich Korolev,A. Kundzer,N. Soroka,A. Kastanayan,T. Povarova,T. Plaksina,O. Antipova,D. Kretchikova,S. Smakotina,O. Tciupa,T. Raskina,T. Kropotina,O. Nesmeyanova,T. Popova,E. Dokukina,A. Plotnikova,A. Lutskii,A. Zinkina-Orihan +18 more
TL;DR: The study confirmed superior efficacy of levilimab +MTX over placebo + MTX in subjects with MTX resistant active RA.
3
Fri0108 short-term efficacy of bcd-089, novel monoclonal anti-il-6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 12-week results of phase 2 aurora study
Vadim I. Mazurov,Evgeniy Zotkin,Elena Ilivanova,T. Kropotina,T. Plaksina,O. Nesmeyanova,N. Soroka,A. Kundzer,Anton Lutskii,E. Dokukina,E. Chernyaeva,Roman Ivanov +11 more
TL;DR: BCD-089 in combination withMTX had superior efficacy compared with MTX plus PBO in MTX-IR patients with active RA and showed safety profile consistent with other IL6R inhibitors, as reported in phase 2 clinical study.
3